Anti-PD-L1 Abs arewidely applied in immunotherapy as checkpoint inhibitors, especiallyin non-small cell lung cancer (NSCLC) but also as treatment in othertypes of cancer, as proven by the three FDA-approved PD-L1 inhibitingAbs currently available in the market.18−20 The therapy is basedon the inhibition of the PD-L1 receptor, upregulated in the microenvironmentof multiple types of cancers. This evidence concerns the gene CD274 and cancer.